Get the Stockscreener App
96.00
0.84%
-0.81
After Hours:
95.98
-0.02
-0.02%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $96.00, with a volume of 9.38M.
It is down -0.84% in the last 24 hours and down -8.97% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$96.81
Open:
$96.5
24h Volume:
9.38M
Relative Volume:
0.77
Market Cap:
$166.82B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
26.74
EPS:
3.5895
Net Cash Flow:
$7.40B
1W Performance:
-4.66%
1M Performance:
-8.97%
6M Performance:
-25.87%
1Y Performance:
-26.71%
1-Day Range:
$95.49
$97.32
1-Week Range:
$93.92
$102.48
52-Week Range:
$93.92
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
How Investors May Respond To Abbott (ABT) Cancerguard Data Amid Legal And Earnings Pressures - simplywall.st
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom - The Motley Fool
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom - The Motley Fool
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account - Investing.com Australia
Abbott Laboratories: The Constraint Is Integration As $3 Billion Bet Adds Complexity! - Smartkarma
Abbott Wins Glucose Monitor Sales Ban On Appeal At UPC - Law360
Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story - Yahoo Finance
SCS Injury Lawsuit Alleges Unlicensed Abbott Representatives Modified Device After Implantation - AboutLawsuits.com
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Guidance Cut - Quiver Quantitative
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Bernstein SocGen cuts Abbott Labs stock price target on weak quarter - Investing.com Canada
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - 24/7 Wall St.
Abbott price target lowered to $143 from $144 at Barclays - TipRanks
Intuitive Surgical (ISRG) Q1 Earnings: What To Expect - TradingView
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to drive sustained growth f - AD HOC NEWS
Abbott Laboratories in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q1; nutrition falls - MSN
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
ABT: Abbott Laboratories Lowers Earnings Outlook Despite Revenue Beat - GuruFocus
How Abbott is Changing the Way We Treat AFib - Tomorrow's World Today
Abbott Laboratories (ABT) Margin Drop To 13.9% Challenges Bullish Earnings Narratives - simplywall.st
Ninety One UK Ltd Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Ninety One North America Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Abbott Laboratories stock (US0028241000): Why diagnostics strength is suddenly worth a closer look - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Short Interest Up 19.4% in March - MarketBeat
Abbott Reaches Preliminary Settlement in Derivative Governance Case - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Why Is Abbott Stock Trending Lower? - Yahoo Finance
[8-K] ABBOTT LABORATORIES Reports Material Event - Stock Titan
ABT Maintained by Piper Sandler -- Price Target Lowered to $115 - GuruFocus
Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings - TipRanks
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi - Yahoo Finance
Abbott Laboratories Sales Growth Outlook 'Leaves Room For Upside': Analyst - Benzinga
Abbott stock crash: Rebound could be coming fast - MSN
Piper Sandler cuts Abbott Labs stock price target on weak diabetes sales - Investing.com
Abbott Stock Crash: Rebound Could Be Coming Fast - MarketBeat
TD Cowen lowers Abbott stock price target to $115 on guidance cut - Investing.com
ABT Maintained by Evercore ISI Group -- Price Target Lowered to $120 - GuruFocus
RBC Capital lowers Abbott Labs stock price target on Q1 results - Investing.com Australia
Abbott Labs’ Financial Results Narrowly Beat Forecasts - Baystreet.ca
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $115 to $144 - Moomoo
Abbott Laboratories (NYSE:ABT) Price Target Cut to $110.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Bernstein SocGen cuts Abbott Labs stock price target on growth concerns - Investing.com Canada
Citigroup Lowers Abbott Laboratories (NYSE:ABT) Price Target to $108.00 - MarketBeat
Wells Fargo Adjusts Price Target on Abbott Laboratories to $109 From $122, Maintains Overweight Rating - Moomoo
Oppenheimer Adjusts Price Target on Abbott Laboratories to $115 From $132, Maintains Outperform Rating - marketscreener.com
Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios - techi.com
Abbott lowers EPS guidance on Exact Sciences buy as shares slide - Fierce Biotech
Citigroup Cuts Price Target on Abbott Laboratories to $108 From $136, Maintains Buy Rating - marketscreener.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):